Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Cash & Equivalents (2021 - 2025)

Medicinova (MNOV) has disclosed Cash & Equivalents for 8 consecutive years, with $30.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents changed N/A to $30.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $30.8 million for FY2025, N/A changed from the prior year.
  • Cash & Equivalents for Q4 2025 was $30.8 million at Medicinova, down from $32.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $77.8 million in Q2 2021, with the low at $30.8 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $53.6 million, with a median of $52.0 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents crashed 30.01% in 2022, then decreased 1.9% in 2023.
  • Over 5 years, Cash & Equivalents stood at $71.4 million in 2021, then fell by 26.49% to $52.5 million in 2022, then dropped by 2.87% to $51.0 million in 2023, then fell by 17.1% to $42.3 million in 2024, then dropped by 27.14% to $30.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $30.8 million, $32.6 million, and $34.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.